Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) from a strong sell rating to a hold rating in a research note published on Monday,Zacks.com reports.

Separately, The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a report on Wednesday, April 8th. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Up 1.2%

OTCMKTS SGIOY opened at $9.33 on Monday. The stock has a 50-day simple moving average of $10.23 and a 200 day simple moving average of $9.86. The company has a market capitalization of $15.88 billion, a PE ratio of 11.66, a P/E/G ratio of 0.68 and a beta of 0.10. The company has a current ratio of 5.84, a quick ratio of 5.21 and a debt-to-equity ratio of 0.01. Shionogi & Co., Ltd. Unsponsored ADR has a 12 month low of $7.65 and a 12 month high of $12.00.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.03. The business had revenue of $881.71 million during the quarter, compared to the consensus estimate of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 14.09% and a net margin of 41.08%. Research analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.78 EPS for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.